Evidence map›Paper›PMID 36716122›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2023

Regular Glucosamine Use May Have Different Roles in the Risk of Site-Specific Cancers: Findings from a Large Prospective Cohort.

Fu-Xiao Li, Hou-Yu Zhao, Teng-Fei Lin, Yi-Wen Jiang, Di Liu, Chang Wei, Zi-Yi Zhao, Zu-Yao Yang, Feng Sha, Zhi-Rong Yang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Fu-Xiao LiShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-1689-9028
Hou-Yu ZhaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.ORCID 0000-0002-4546-9342
Teng-Fei LinShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0001-5282-6945
Yi-Wen JiangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0003-0315-8180
Di LiuShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0003-4493-4772
Chang WeiShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0003-2378-1658
Zi-Yi ZhaoShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-3133-3460
Zu-Yao YangDivision of Epidemiology, JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-2386-2431
Feng ShaShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-0966-5733
Zhi-Rong YangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-1562-0603
Jin-Ling TangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-4516-8179
Shenzhen Institutes of Advanced Technology · CNChinese University of Hong Kong · HKGuangzhou Women and Children Medical Center · CNPeking University · CN

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

backgroundPrevious studies indicated that glucosamine supplements may have a general anticancer effect. This study aimed to assess whether the potential effect differs across different types of cancers in a large prospective cohort study.

methodsAll participants from the UK Biobank who were free of cancers and had complete information on glucosamine use at baseline were included and followed up from 2006 until 2021. Cox proportional hazards models were used to assess the associations between regular glucosamine use and different site-specific cancers. Subgroup analyses were performed to explore potential interactions. Several sensitivity analyses were conducted to assess the robustness of the main findings.

resultsA total of 450,207 eligible participants (mean age: 56.2 years; females: 53.3%) were included, of whom 84,895 (18.9%) reported regular glucosamine use at baseline. During a median of 12.5 years follow-up, glucosamine use was significantly associated with an increased risk of overall cancer [HR, 1.04; 95% confidence interval (CI), 1.01-1.06], skin cancer (HR, 1.11; 95% CI, 1.07-1.15), and prostate cancer (HR, 1.07; 95% CI, 1.01-1.13), and with a reduced risk of lung cancer (HR, 0.88; 95% CI, 0.79-0.97) after adjusting for potential confounders. Statistical interaction was observed for gender, age, and education for the association of glucosamine use with overall cancer risk (all Pinteraction < 0.027). These results remained unchanged in the sensitivity analyses.

conclusionsRegular glucosamine use was associated with lower risk of lung cancer but higher risk of skin cancer, prostate cancer, and overall cancer. IMPACT: The roles of glucosamine use potentially differ in the development of different site-specific cancers.

Indexed as

Lung NeoplasmsProstatic NeoplasmsSkin NeoplasmsDietary SupplementsGlucosamineHumansMaleMiddle AgedProspective StudiesRisk FactorsGlucosamine

Identifiers

PMID36716122
PMCPMC10068435
OpenAlexW4318542513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.